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Cilia are highly specialized cellular organelles that serve multiple functions in human
development and health. Their central importance in the body is demonstrated by the
occurrence of a diverse range of developmental disorders that arise from defects of cilia
structure and function, caused by a range of different inherited mutations found in more
than 150 different genes. Genetic analysis has rapidly advanced our understanding of
the cell biological basis of ciliopathies over the past two decades, with more recent
technological advances in genomics rapidly accelerating this progress. The 100,000
Genomes Project was launched in 2012 in the UK to improve diagnosis and future
care for individuals affected by rare diseases like ciliopathies, through whole genome
sequencing (WGS). In this review we discuss the potential promise and medical impact
of WGS for ciliopathies and report on current progress of the 100,000 Genomes Project,
reviewing the medical, technical and ethical challenges and opportunities that new, large
scale initiatives such as this can offer.
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THE 100,000 GENOMES PROJECT
The launch of the UK’s 100,000 Genomes project was announced in December 2012 as part of
the UK’s Life Sciences Strategy. This ambitious £300 million national project aimed to sequence
100,000 complete genomes from 70,000 individuals with cancer or rare disease, and their unaffected
family members (Turnbull et al., 2018). Unlike other population genomics studies such as those in
Iceland, Japan, Finland, Sweden and the Netherlands (An, 2017), the 100,000 Genomes Project
is a hybrid clinical/research initiative, with an aim to fully integrate genomic testing for eligible
individuals within existing routine healthcare pathways in the UK National Health Service (NHS).
Sequence data is linked to longitudinal patient records such as hospital admissions and responses
to interventions, providing a rich resource of genomic medical information. In many respects, it is
the first scheme of its kind in the world, and one of the largest.
The project built upon the legacy of successful population healthcare genetics studies in the UK,
such as the Deciphering Developmental Disorders (DDD) study (Wright et al., 2015) and UK10K
(Consortium et al., 2015) which built upon the Avon Longitudinal Study of Parents And Children
(ALSPAC) (Boyd et al., 2013) and TwinsUK (Moayyeri et al., 2013). It aims to secure the UK’s
position as a world-leader in healthcare and genomics.
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FIGURE 1 | Proportion of families and individuals with different disorders
within the rare disease cohort of the 100,000 Genomes Project. Around 1% of
recruited families/individuals have a ciliopathy. Cohort summary data courtesy
of Genomics England, with permission.
Recruitment for the 100,000 Genome Project has been
coordinated across 13 Genomic Medicine Centers set up across
85 NHS Trusts in England, Northern Ireland and Scotland. Of
the estimated 8,000 rare diseases (Boycott et al., 2017), 190 were
recruited to the Rare Disease pathway of the 100,000 Genomes
Project, from 2015/16 until 31st September 2018. Eligible rare
diseases were nominated by clinicians and researchers who felt
there was an unmet clinical need, for example, diseases for
which there are a sizeable proportion of patients with no known
genetic diagnosis. The range of phenotypes and the proportion of
patients with different disorders within the rare disease cohort is
shown in Figure 1. Where possible, “trios” were recruited, i.e., the
affected individual and both parents, with efforts made to recruit
both affected and unaffected family members to allow effective
variant filtration.
GENETIC BASIS OF
CILIOPATHIES—DISEASES AFFECTING
CILIA STRUCTURE AND FUNCTION
Ciliopathies represent one group of rare diseases recruited to
the 100,000 Genomes project. The ciliopathies are a diverse
grouping but have a common etiology, originating in ciliogenesis
(growth andmaintenance) and/or structural or functional defects
of the cilium (Reiter and Leroux, 2017). Cilia are highly evolved,
complex organelles with important roles inmotility and signaling
(Waters and Beales, 2011; Mitchison and Valente, 2017; Wheway
et al., 2018). The extent of the overall medical impact of
ciliopathies, which individually most often are rare conditions
but collectively affect a large number of individuals, has emerged
over the last 20 years as their functions have continued to be
revealed through genetic analysis in animal models and human
families (Fliegauf et al., 2007; Goetz and Anderson, 2010).
Cilia can broadly be divided into motile and non-motile
(primary), each with separate functions, both of which form
a unique cellular compartment distinct from the rest of the
cell. Primary cilia are more ubiquitous, distributed across most
cell types of the body, extending out from the cell surface
into their external environment as a single projection with
diverse mechanosensory and chemosensory signal transduction
roles (Singla and Reiter, 2006). The photoreceptors of the eye
have a modified cilium, the outer segment (Wright et al.,
2010). In contrast, motile cilia are found only on specialized
epithelial surfaces and usually as multiple motile cilia (perhaps
200 per cell). Motile cilia lining notably the respiratory airways,
brain ventricles and fallopian tubes, move essential body fluids
and gametes, with a structural composition related to that
of sperm flagella in male gamete movement (Spassky and
Meunier, 2017). Single motile nodal cilia that exist transiently
in the embryonic left-right organizer function in laterality
determination (Hamada, 2016).
Owing to the central role of the cilium in development
and health, ciliopathies often include complex multi-organ
developmental phenotypes. The most severe-lethal ciliopathies,
Meckel-Gruber syndrome (MKS) (Wheway and Johnson, 2014;
Hartill et al., 2017), Joubert syndrome (JBTS) (Parisi and
Glass, 1993; Bachmann-Gagescu et al., 2015), orofacial digital
syndrome (OFD) (Gurrieri et al., 2007) as well as Bardet-
Biedl syndrome (BBS) (Forsythe and Beales, 2013), all include
neurodevelopmental features. These are often present alongside
other features such as retinal dystrophy, renal dysplasia and
skeletal abnormalities (Waters and Beales, 2011). Skeletal
ciliopathies range from lethal short-rib thoracic dysplasias to
more mild phenotypes such as Jeune syndrome (Huber and
Cormier-Daire, 2012; Mitchison and Valente, 2017; Schmidts
and Mitchison, 2018). Renal ciliopathies are some of the most
common conditions associated with cilia defects. Autosomal
polycystic kidney disease (ADPKD) alone affects between 1:2,500
and 1:4,000 individuals in the EU, making it one of the most
common genetic diseases in humans, and the most common
cause of end–stage renal failure (Willey et al., 2017). Renal
malformations can also take the form of nephronophthisis,
characterized by chronic tubulointerstitial nephritis, in isolated
conditions or part of multiorgan ciliopathies including Senior-
Loken syndrome (Wolf and Hildebrandt, 2011). Due to the
importance of the highly specialized photoreceptor cilium
in the function of the retina, many syndromic ciliopathies
include a retinal dystrophy phenotype. Furthermore, around
one third of non-syndromic inherited retinal dystrophies,
such as retinitiris pigmentosa (RP) and Leber congenital
amaurosis (LCA), are associated with a retinal cilium defect
(Estrada-Cuzcano et al., 2012). These are termed retinal
ciliopathies (Bujakowska et al., 2017).
Rather than being distinct clinical entities, ciliopathies are
considered to form a spectrum of disorders, with considerable
phenotypic and genotypic overlap between different conditions.
In addition to this, there is also extensive phenotypic and genetic
heterogeneity amongst ciliopathies (Mitchison andValente, 2017;
Oud et al., 2017). There are currently at least 190 known
ciliopathy disease genes causing defects of the primary cilia
(Table 1), and mutations in many of the same genes can cause
strikingly different phenotypes. A classic example is CEP290,
mutations in which can cause perinatal lethal MKS, severe JBTS,
or non-syndromic LCA, which only affects the retina (Coppieters
et al., 2010; Drivas and Bennett, 2014).
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TABLE 1 | Overview of genes mutated in ciliopathies showing the heterogeneity of
certain ciliopathies.
Gene OMIM Description
NEURODEVELOPMENTAL CILIOPATHIES
AHI1 608894 JBTS
ARL3 604695 JBTS, RP?
ARL13B 608922 JBTS
ARMC9 NA JBTS
ATXN10 611150 JBTS-like
B9D1 614144 MKS
B9D2 611951 MKS
C5orf42 614571 JBTS, OFDS
CC2D2A 612013 JBTS, MKS
CELSR2 604265 JBTS-like
CEP104 616690 JBTS
CEP120 613446 JBTS, SRTD
CEP290 610142 JBTS, SLSN, LCA,
MKS, BBS
CEP41 610523 JBTS
CEP55 610000 MKS-like
CLUAP1 616787 JBTS, OFDS
CPLANE1 614571 JBTS
CSPP1 611654 JBTS
EXOC4 608185 MKS
EXOC8 615283 JBTS
HYLS1 610693 MKS-like
ICK 612325 ECO
IFT81 605489, 617895 JBTS-like, SRTD
INPP5E 613037 JBTS
KIAA0556 616650 JBTS
KIAA0586 610178, 616546 JBTS, SRTD
KIF14 611279 MKS, microcephaly
with kidney defects
KIF7 611254 JBTS, MKS-like, ACLS
MKS1 609883 MKS, BBS, JBTS
NPHP1 607100 JBTS, NPHP, SLSN
NPHP3 608002 MKS, NPHP
OFD1 300170 JBTS, OFDS
PDE6D 602676 JBTS
PIBF1 607532 JBTS
RPGRIP1L 610937 JBTS, MKS
SUFU 607035 JBTS
TCTN1 609863 JBTS
TCTN2 613846 JBTS
TCTN3 613847 JBTS, OFDS
TMEM107 616183 MKS, OFDS
TMEM138 614459 JBTS
TMEM216 613277 JBTS, MKS
TMEM231 614949 JBTS, MKS
TMEM237 614423 JBTS
TMEM67 609884 MKS, JBTS, NPHP,
BBS
TTBK2 611695 JBTS-like
ZNF423 604557 JBTS, NPHP
(Continued)
TABLE 1 | Continued
Gene OMIM Description
CILIOPATHIES WITH MAJOR SKELETAL INVOLVEMENT
C2CD3 615944 OFDS
CEP120 613446 SRTD
C21ORF2 603191 JATD
DDX59 615464 OFDS
DYNC2LI1 617083 SRTD
DYNC2H1 603297 JATD, SRTD
EVC 604831 EVC, WAD
EVC2 607261 EVC, WAD
IFT122 606045 CED
IFT140 614620 SRTD, RP
IFT172 607386 JATD, MZSDS, SRTD,
RP
IFT43 614068 CED, SRTD, RP
IFT52 617094 SRTD +/− polydactyly
+/− LCA
IFT80 611177 JATD, SRTD +/−
retinal dystrophy
INTU 610621 OFDS? SRTD +
polydactyly?
KIAA0753 617112 OFDS? JBTS?
NEK1 604588 SRTD
OFD1 300170 OFDS, SGBS, JBTS
SCLT1 611399 OFDS
TBC1D32 615867 OFDS
TCTEX1D2 617353 JATD, SRTD
TTC21B 612014 JATD, NPHP
WDR19 608151 JATD, CED, NPHP,
SLSN
WDR34 613363 JATD, SRTD
WDR35 613602 EVC, CED, SRTD
WDR60 615462 JATD, SRTD
ISOLATED AND SYNDROMIC OBESITY
ALMS1 606844 ALMS
ARL6 608845 BBS, RP
BBIP1 613605 BBS
BBS1 209901 BBS
BBS10 610148 BBS
BBS12 610683 BBS
BBS2 606151 BBS, RP
BBS4 600374 BBS
BBS5 603650 BBS
BBS7 607590 BBS
BBS9 (PTHB1) 607968 BBS
C8orf37 614477 BBS, CORD, RP
CCDC28B 610162 BBS
CEP19 615586 MOSPGF
IFT27 615870 BBS, unclassified lethal
ciliopathy with renal
involvement
IFT74 608040 BBS
LZTFL1 606568 BBS
(Continued)
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TABLE 1 | Continued
Gene OMIM Description
MKKS 604896 BBS, MKKS
TRIM32 602290 BBS
TTC8 608132 BBS, RP
WDPCP 613580 BBS
RENAL CILIOPATHIES
ANKS6 615370 NPHP
CEP164 614848 NPHP
CEP83 615847 NPHP
DCDC2 605755 NPHP
GLIS2 608539 NPHP
INVS 243305 NPHP
IQCB1 609237 SLSN
MAPKBP1 616786 NPHP
NEK8 609799 NPHP
NPHP4 607215 NPHP, SLSN
PKD1 601313 ADPKD
PKD2 173910 ADPKD
PKHD1 606702 ARPKD
SDCCAG8 613524 SLSN, BBS
TRAF3IP1 607380 SLSN
VHL 608537 VHL
XPNPEP3 613553 NPHP-like
ISOLATED RETINAL CILIOPATHY
C21orf71 613425 RP
CDHR1 609502 RP, CORD
CLRN1 (USH3A) 606397 RP, USH
EYS 612424 RP
LCA5 611408 LCA
MAK 154235 RP
PRPF3 607301
PRPF31 606419 RP
PRPF4 607795 RP
PRPF6 613979 RP
PRPF8 607300 RP
RP1 603937 RP
RPGR 312610 RP, PCD
RPGRIP1 605446 LCA
SNRNP200 601664 RP
SPATA7 609868 RP, LCA
TOPORS 609507 RP
TULP1 602280 RP, LCA
USH2A 608400 RP, USH
RETINAL DYSTROPHY WITH SENSORINEURAL HEARING LOSS
ADGRV1 602851 USH
ARSG 610008 USH
CDH23 605516 USH
CEP78 617110 CORD + deafness
CIB2 605564 USH
HARS 142810 USH
MYO7A 276903 USH
PCDH15 605514 USH
(Continued)
TABLE 1 | Continued
Gene OMIM Description
PDZD7 612971 USH
SANS 607696 USH
TUBB4B 602662 LCA with early-onset
hearing loss
USH1C 605242 USH
USH1E 602097 USH
USH1H 612632 USH
USH1K 614990 USH
WHRN 607928 USH
OTHER CILIOPATHIES
CENPF 600236 Microcephaly, agenesis
of corpus callosum
CCDC11 614759 Laterality defects
CDK10 603464 Suspected complex
multisystem ciliopathy
affecting development,
speech with agenesis
of corpus callosum,
sensorineural deafness,
retinitis pigmentosa,
vertebral anomalies,
patent ductus
arteriosus, facial
dysmorphism
SPAG17 616554 Brain malformations,
CED-like skeletal
dysplasia
WDR11 606417 congenital
hypogonadotropic
hypogonadism,
Kallmann syndrome
PRIMARY CILIARY DYSKINESIA
ARMC4 615408 PCD
C21orf59 615494 PCD
CCDC103 614677 PCD
CCDC114 615038 PCD
CCDC151 615956 PCD
CCDC39 613798 PCD
CCDC40 613799 PCD
CCDC65 611088 PCD
CCNO 607752 PCD
CFAP300 618058 PCD
DNAAF1 613190 PCD
DNAAF2 612517 PCD
DNAAF3 614566 PCD
DNAAF4 608706 PCD
DNAAF5 614864 PCD
DNAH1 603332 Male infertility, PCD
association
DNAH11 603339 PCD
DNAH5 603335 PCD
DNAH9 603330 PCD
DNAI1 604366 PCD
DNAI2 605483 PCD
DNAJB13 610263 PCD
(Continued)
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TABLE 1 | Continued
Gene OMIM Description
DNAL1 610062 PCD
DRC1 615288 PCD
GAS8 605179 PCD
HYDIN 610812 PCD
LRRC6 614930 PCD
LRRC56 N/A Mucociliary clearance
and laterality defects
MCIDAS 614086 PCD
MNS1 610766 Male infertility, laterality
defects
NME8 607421 PCD
PIH1D3 300933 PCD
RSPH1 609314 PCD
RSPH3 615876 PCD
RSPH4A 612647 PCD
RSPH9 612648 PCD
SPAG1 603395 PCD
STK36 607652 PCD
TTC25 617095 PCD
ZMYND10 607070 PCD
Modified from Oud et al. (2017).
ACLS, acrocallosal syndrome; ADPKD, autosomal dominant polycystic kidney disease;
ALMS, Alström syndrome; ARPKD, autosomal recessive polycystic kidney disease;
BBS, Bardet-Biedl syndrome; CED, cranioectodermal dysplasia syndrome; CORD,
cone-rod dystrophy; ECO, endocrine-cerebro-osteodysplasia syndrome; EVC, Ellis-
van Creveld syndrome; JATD, Jeune asphyxiating thoracic dysplasia; JBTS, Joubert
syndrome; LCA, Leber congenital amaurosis; MKKS, McKusick-Kaufman syndrome;
MKS, Meckel-Gruber syndrome; MOSPGF, morbid obesity and spermatogenic failure;
NPHP, nephronophthisis; OFDS, oral-facial-digital syndrome; PCD, primary ciliary
dyskinesia; RP, retinitis pigmentosa; SGBS, Simpson-Golabi-Behmel syndrome; SLSN,
Senior-Løken syndrome; SRTD, short-rib thoracic dysplasia; USH, Usher syndrome;
VHL, von Hippel-Lindau syndrome; WAD, Weyers acrodental dysostosis. OMIM: ID
number in Online Mendelian Inheritance in Man (https://omim.org/). NA: OMIM number
is not available.
Motile ciliopathies are grouped under the name primary
ciliary dyskinesia (PCD). A component of PCD manifests with
left-right axis abnormalities and this association is also called
Kartagener’s syndrome, which affects around 50% of PCD
patients; additionally there is a more rare disease component
arising from defects of ciliogenesis affecting cilia numbers,
which is also being called reduced generation of multiple
motile cilia (RGMC) (Boon et al., 2014; Lucas et al., 2014;
Knowles et al., 2016). Apart from laterality defects that may
be linked to cardiac disease (Best et al., 2018), PCD disease
features include chronic respiratory infections from earliest life,
progressive upper respiratory problems and loss of lung function
(bronchiectasis), conductive hearing problems, subfertility, and
infrequent hydrocephalus. The same as for the nonmotile
ciliopathies, PCD is a genetically and clinically heterogeneous
condition, with mutations in around 40 different motile cilia
genes currently recognized to cause disease (Table 1). Similarly
to the primary ciliopathies, a wider than previously suspected
spectrum of motile ciliopathy disease is starting to emerge
with greater genetic understanding of these conditions. Gene
mutations causing more severe (Davis et al., 2015; Amirav et al.,
2016; Irving et al., 2018) and more mild (Knowles et al., 2014;
Lucas et al., 2017b; Best et al., 2018; Irving et al., 2018; Shoemark
et al., 2018) disease have more recently been recognized, as
well as subtypes with features that overlap with the primary
ciliopathies such as retinitis pigmentosa and developmental delay
(Budny et al., 2006; Moore et al., 2006). These syndromic disease
subtypes e.g. Simpson-Golabi-Behmel type 2 syndrome, expand
our understanding of the extent of the motile ciliopathy disease
spectrum (Mitchison and Shoemark, 2017).
CHALLENGES OF DIAGNOSING
CILIOPATHIES USING GENOMICS
Despite advances in genetic understanding of these conditions
with the advent of next generation sequencing, ciliopathies
remain under-diagnosed and poorly recognized due to
insensitive and non-specific aspects of available diagnostic
tests, compounded by variable disease features. Genetic
diagnostic rates of severe primary ciliopathies remain around
62% using targeted gene panel sequencing (Bachmann-Gagescu
et al., 2015; Knopp et al., 2015) and 44% using whole exome
sequencing (Sawyer et al., 2016). The diagnostic rate of the
arguably more uniform motile ciliopathies disease grouping is
higher, using well-characterized cohorts, at up to 67% using
targeted gene panels (Boaretto et al., 2016; Paff et al., 2018)
and 76% using whole exome sequencing with targeted copy
number variation (CNV) analysis (Marshall et al., 2015). For
both the primary and motile ciliopathies, many genetic causes
of these conditions remain unknown. There remain very few, if
any, treatment options for the vast majority of these conditions
(Lucas et al., 2014, 2017a; Molinari and Sayer, 2017). Thus, there
is a pressing clinical need to advance genetic understanding
for the purpose of diagnostics, prognostics and development of
novel targeted therapies. Clinical genome data from the 100,000
Genomes Project presents exciting opportunities to offer patients
genetic diagnoses, gain novel insights into etiology of disease,
and uncover new targets for therapies.
Ciliopathy patients and family members account for around
1% of the rare disease cohort recruited to the UK 100,000
Genomes Project (Figure 1). In the majority of cases, patients
recruited to the ciliopathy pathway have had the relevant
ciliopathy disease genes sequenced and excluded as the
cause of their disease. Such testing is provided as a genetic
diagnostic service by accredited NHS genomics labs, and involves
sequencing the exons and intron/exon boundaries of a panel of
currently 123 genes known to be mutated in ciliopathies.
At the time of writing, genomes have been sequenced and
analyzed from 274 patients and family members with respiratory
ciliopathies (126 PCD patients, 148 non-cystic fibrosis (CF)
bronchiectasis patients and family members) and 81 patients
and family members with congenitial malformations caused by
ciliopathies (45 BBS, 14 JBTS, 22 rare multisystem ciliopathy
disorders). These numbers will increase as sequencing and
analysis is ongoing. However, it is likely that a much larger
number of ciliopathy patients have been recruited to the
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project within other categories such as “renal and urinary
tract disorders,” which includes phenotypic descriptor “cystic
kidney disease” which accounts for 1,516 individuals alone.
Furthermore, within the “ophthalmological disorders” category
there are likely to be many undiagnosed retinal ciliopathy
patients. One thousand two hundred and sixty individuals
with a diagnosis of rod-cone dystrophy or LCA)/early onset
severe retinal dystrophy have been recruited. It can be
estimated that around one third of these patients have a
retinal dystrophy owing to a retinal photoreceptor cilium defect
(Estrada-Cuzcano et al., 2012). There are many patients in the
project with other dysmorphic and congenital abnormalities
with features overlapping ciliopathy phenotypes, which may
be undiagnosed ciliopathies. This includes 19 patients with
unexplained monogenic fetal disorders. Similarly, there are more
than 6,000 patients (39% of the total rare disease patient cohort,
Figure 1) with a general neurology or neurodevelopmental
disorder. These include patients with intellectual disability,
holoprosencephaly and hereditary ataxia, all of which are
ciliopathy phenotypes seen in syndromic ciliopathies. A subset of
these patients could also have undiagnosed ciliopathies. Numbers
will increase as data from more patients is made available in
upcoming data releases. The 100,000 Genomes Project may thus
represent a unique opportunity to discover and diagnose orphan
ciliopathies in patients whose phenotype does not currently easily
fit into existing disease categories.
The success of the project may lie in the accuracy and
thoroughness of phenotyping information provided i.e., the
consistent use of Human Phenotype Ontology (HPO) terms. The
HPO systemwas developed to annotate clinical disease terms and
definitions with a standardized phenotypic vocabulary (Robinson
et al., 2008; Köhler et al., 2017). A particular difficulty with
ciliopathies is that they are extremely heterogeneous conditions
and it has been suggested that clinicians should be encouraged
to actively involve patients in describing their own phenotype
(Gainotti et al., 2018). There is great power in larger collections
of well-defined patient cohorts to support better clinical research
and diagnostics, with the development of rare disease patient
registries being a key component supporting the activities of
European Reference Networks (ERNs) on rare diseases (Kodra
et al., 2018). The European Organization for Rare Diseases
(EURORDIS) has developed recommendations on ethical and
responsible international data sharing to help inform a clinical
diagnosis (Gainotti et al., 2018).
A wide range of phenotypes of different severities are
associated with the ciliopathies, demonstrating their complexity
(Lee and Gleeson, 2011; Arts and Knoers, 2013; Mitchison
and Valente, 2017). Figure 2 is not exhaustive but shows
selected clinical features of the ciliopathies, highlighting
those relevant to recruitment criteria for 100,000 Genomes
Project. This is a constantly expanding spectrum, with motile
and non-motile cilia recently implicated in the etiology of
congenital heart disease (You et al., 2015; Best et al., 2018).
Situs inversus and associated cardiac malformations found in
common between motile and some nonmotile ciliopathies
suggest an influence on laterality determination at the
embryonic left-right organizer during development from
non-motile as well as motile cilia, or else that there are shared
motile cilia defects, or a mixture of both. There is growing
evidence for respiratory involvement in the non-motile primary
ciliopathies, but the molecular basis of these findings remains
unclear (Mitchison and Shoemark, 2017).
In terms of genetic heterogeneity, interpreting large volumes
of genetic variants from all of the ciliopathy patients in order
to identify the truly pathogenic disease-causing variant in each
individual represents a major challenge. In addition to primary
causal variants, modifier genes and variable mutational load have
been proposed to play roles in determining the genetic spectrum
for both primary ciliopathies (Katsanis et al., 2001; Davis et al.,
2011; Zaki et al., 2011; Lindstrand et al., 2016) and motile
ciliopathies (Li et al., 2016). Different mutation types can be
expected in different ciliopathies, for example motile cilia disease
tends to arise from high impact pathogenicity mutations, most
often single base substitutions, small insertions and deletions or
larger CNVs, that result in protein frameshifts, premature stop
codons, missense changes, or splicing defects giving rise to null
alleles effects. In contrast, for the non-motile primary ciliopathies
lethality frequently arises as a consequence of such alleles, whilst
surviving patients would carry only one or no copies of this type
of high impact allele, but instead carry one or two hypomorphic
alleles such as milder effect missense changes (Davis et al.,
2011; Hildebrandt et al., 2011; Schmidts et al., 2013; Reiter and
Leroux, 2017). Some specific mutations may be expected, for
example splicing mutations and CNVs are common in retinal
degeneration caused by PRPF31 mutations (Buskin et al., 2018).
With the superior detection of many mutations through whole
genome sequencing, the genetic landscape is expected to greatly
expand and may significantly change with implementation of
large scale whole genome sequencing (Belkadi et al., 2015). For
example the 100,000 Genome Project has already detected a
deep intronic mutation in DNAH11 causing PCD which would
not have been detected by other current clinical screening
methods (Ellingford et al., 2018).
CILIOPATHY GENOMICS DATA ANALYSIS
IN THE 100,000 GENOMES PROJECT
Genomics England Clinical Interpretation Partnerships (GeCIPs)
currently coordinate a crowdsourcing approach to data analysis,
building on the success of aggregate consortia such as the
Exome Aggregation Consortium (ExAc) (Karczewski et al.,
2017) and Genome Aggregation Database (GnomAD) (Lek
et al., 2016), and public databases such as ClinVar (Landrum
and Kattman, 2018), Human Gene Mutation Database HGMD
(Stenson et al., 2017) and the Leiden Open-source Variation
Database LOVD (Fokkema et al., 2011). In addition to GeCIPs,
formed of individuals from not-for-profit organizations, such
as academics and clinicians who must apply for access to
anonymized data, private commercial companies also have
access to the anonymized data. The project is achieved through
public-private partnerships (PPPs) between Genomics England
Limited, owned by the UK Government’s Department of Health
& Social Care, and private companies including Illumina Inc.
Illumina is a partner both in sequencing and bioinformatics data
analysis (https://www.genomicsengland.co.uk/bioinformatics-
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FIGURE 2 | Overlapping disease features of the ciliopathies. This is not an exhaustive list but illustrates the complex phenotypes and overlapping clinical features of
ciliopathies. The severe/lethal diseases tend to have more complex combinations of disease features, compared to diseases at the milder end of the clinical spectrum.
Situs inversus and associated cardiac malformations are found in common between non-motile and motile ciliopathies and the former can also display respiratory
defects. ALMS, Alström syndrome; BBS, Bardet-Biedl syndrome; JATD, Jeune asphyxiating thoracic dysplasia; JBTS, Joubert syndrome; LCA, Leber congenital
amaurosis; MKS, Meckel-Gruber syndrome; NPHP, nephronophthisis; OFD, oral-facial-digital syndrome; PCD, primary ciliary dyskinesia; PKD, polycystic kidney
disease; RP, retinitis pigmentosa; USH, Usher syndrome.
partnership-with-illumina/). Other “interpretation partners”
include Congenica, ICON, Fabric Genomics andWuxiNextCode
(https://www.genomicsengland.co.uk/the-100000-genomes-
project/data/current-research/). Further to this, industrial
companies have been invited to engage with the project and
access data by joining the Genomics Expert Network for
Enterprises (GENE) for a fee.
Currently, novel or rare variants identified in rare disease
patients in the 100,000 Genomes Project are “tiered” according
to predicted pathogenicity, following the Association for
Clinical Genetic Science’s Best Practice Guidelines for Variant
Classification (https://www.acgs.uk.com/quality/best-practice-
guidelines/) which builds upon Standards and Guidelines
for the Interpretation and Reporting of Sequence Variants in
Cancer published by the Association for Molecular Pathology
(Li et al., 2017). This allows classification of variants into Tier
1, variants with strong clinical significance; Tier 2, variants
with potential clinical significance; Tier 3, variants of unknown
clinical significance; and Tier 4, variants deemed benign or
likely benign. Tiering is achieved using information from
PanelApp, an online resource in which clinicians, academic
researchers and laboratory scientists pool information about
known disease genes, and pathogenic variants within them
(https://panelapp.genomicsengland.co.uk/). This crowdsourcing
tool enables a “virtual gene panel” approach to the analysis
of genomic data; focusing on known or predicted pathogenic
genes and variants. Patients’ genomes are first analyzed against
a panel of genes most closely associated with their disease
phenotype (i.e., ciliopathy gene panels), then against other
suitable gene panels with features overlapping the phenotype
e.g., retinal dystrophy gene panel, neurology panel. Tier 1
variants are protein truncating (frameshift, stop gain, stop
loss, splice acceptor variant, or splice donor variant) or de
novo (protein truncating, missense, or splice region) variants
in at least one transcript of a gene on the diagnostic grade
“green” gene list in the virtual gene panel for the disorder in
question. Tier 2 variants are protein altering variants, such as
missense and splice region variants, in at least one transcript
of a gene on the diagnostic grade “green” gene list in the
virtual gene panel for the disorder in question. Tier 1 and
2 variants are not commonly found in the general healthy
population, the allelic state matches the known mode of
inheritance for the gene and disorder, and segregates with
disease (where applicable). Protein truncating, de novo or protein
altering variants affecting genes not in the virtual gene panel
are Tier 3. If a variant does not meet any of these criteria it
is untiered1.
To provide some sense of scale of the challenge faced,
at the time of going to press, there were 2,605 Tier 3
variants in probands with the phenotype “primary ciliary
disorders;” primary ciliary dyskinesia’ and “primary ciliary
dyskinesia::primary ciliary disorders.” Of these, 174 are
frameshift/stop gain/stop loss/splice donor variant/splice
1For further information we direct readers to https://panelapp.genomicsengland.
co.uk/
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acceptor variants i.e., presumed loss-of function, and 1,829
are missense variants, in around 115 genes. Similarly, at the
time of going to press, there were 4,518 Tier 3 variants in
probands with phenotype “Bardet-Biedl syndrome;” “Joubert
syndrome” or “rare multisystem ciliopathy disorders.” Of these,
506 are frameshift/stop gain/stop loss/splice donor variant/splice
acceptor variant i.e., presumed loss-of function, and 3,028 are
missense variants. Characterizing the effect of these mutations
poses a significant challenge in terms of computing power,
manpower and bioinformatics expertise.
MOLECULAR MODELING OF
CILIOPATHIES
Traditional approaches to modeling non-motile ciliopathies
involve 2D ciliated cell line cultures (Table 2) or whole animal
studies, typically zebrafish (Marshall and Osborn, 2016; Song
et al., 2016), mice (Norris and Grimes, 2012), Xenopus (Walentek
and Quigley, 2017; Blum and Ott, 2018), chick (Schock et al.,
2016) and C.elegans (Mok and Héon, 2012). Study of motile
ciliopathies usually involves studying cells in vivo, or on ex
vivo cultures such as mouse tracheal explants or nasal brush
samples from patients with PCD, grown at the air-liquid interface
(ALI) (Hirst et al., 2010). There are no adherent immortalized
cell lines which can grow motile cilia, although a recent paper
reported the immortalization of a multiciliated cell line with
dyskinetic cilia (Kuek et al., 2018) which is unlikely to be
useful as a control for studying motile ciliopathies. Much
understanding of motile cilia has been achieved using single
celled flagellated organisms such as Chlamydomonas reinhardtii
(Harris et al., 2009) and Trypanosoma brucei (Langousis and
Hill, 2014) which possess one and two flagella, respectively.
More recent models include multiciliates planaria and paramecia
(King and Patel-King, 2016; Fassad et al., 2018). These model
systems offer numerous advantages, including ease of culture
and biochemical purification of motile cilia and ease of genetic
manipulation. For a useful review of cilia model organisms, see
(Vincensini et al., 2011).
3D organoids derived from human embryonic stem (ES)
cells or induced pluripotent stem cell (iPSCs) are increasingly
replacing animals in ciliopathy research. These can be derived
from patient fibroblasts, or can be genetically engineered to
harbor patient mutations, to study effect of mutation and efficacy
of possible treatments. In the past decade, techniques have
particularly advanced in culture methods for producing in vitro
3D cell culture models to study cilia and ciliopathies. These
include urine-derived renal epithelial cells (URECs) (Ajzenberg
et al., 2015) and models of mammalian retina for studying retinal
ciliopathies. Robust protocols for culture of retinal organoids
from human embryonic stem (ES) cells and induced pluripotent
stem cells (iPSCs) have been published and refined (Meyer
et al., 2011; Kuwahara et al., 2015). These organoids form
laminated neural retina with mature photoreceptor cells, which
can be selectively isolated using specific cell surface markers
(Lakowski et al., 2018). This provides a highly relevant human-
derived model for studying retinal development and retinal
degeneration. This is particularly useful for studying human
retinal dystrophies which are not recapitulated in genetic mouse
models, such as knock-in and knock-out mice models of RP
associated with pre-mRNA splicing factor 31 mutations, which
do show photoreceptor degeneration (Bujakowska et al., 2009).
Similarly, culture techniques are advancing toward the ability to
grow motile ciliated cells from iPSCs and ES cells, including in
3D spheroids (Firth et al., 2014; Konishi et al., 2016).
Techniques for genetically editing these ciliated cell models
are also advancing, where primary patient cells are not suitable
or available for research. This field is moving toward a point
where investigators can replicate a potentially pathogenic variant
of unknown clinical significance in a human ES cell or iPSC,
and differentiate these cells toward a cell type relevant to the
primary disease tissue to study the effect of mutation and
evaluate methods of genetic correction. Since the development
of zinc finger nucleases (ZFNs) (Bibikova et al., 2003) and
transcription activator-like effector nucleases (TALENs) (Wood
et al., 2011) it has been possible to edit the genome with
a high degree of accuracy, to introduce DNA double strand
breaks at specific genomic locations, which are generally
repaired by error-prone non-homologous end joining (NHEJ)
introducing small insertions or deletions, in order to create
specific genetic knockouts. However, design and production of
such zinc finger nucleases was slow and laborious. It is now
possible to introduce such specific breaks with one common
nuclease; Cas9 nuclease, significantly increasing throughput.
Cas9 is targeted to the genome using a specific guide RNA,
in a process termed Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPR)/Cas9 genome editing (Cong
et al., 2013). The development of the “dual nickase” approach
increases specificity and reduces off-target effects (Ran et al.,
2013) but off-target effects remain one of the major challenges
of scientists using CRISPR. Whilst knockouts can be generated
at high efficiency, relying on NHEJ, the introduction of specific
insertions, deletions, transitions or transversions using a specific
repair template via homology directed repair (HDR), occurs at
significantly lower frequency.
In response to this, investigators have now developed base
editing, a modified form of CRISPR/Cas9 genome editing, in
which Cas9 nickase (Cas9n) is tethered to a cytidine deaminase
enzyme which catalyzes the efficient conversion of C•G>T•A
changes within a specific window of activity (Komor et al.,
2016; Koblan et al., 2018). This refined genetic system can
be used to study specific dominant, recessive and compound
heterozygous mutations in relevant cells, or animal models.
Recently, new adenine base editing tools have been developed,
which enable engineering of specific A•T>G•C changes in
cell lines (Gaudelli et al., 2017; Koblan et al., 2018). Both
technologies have been optimized for mutation in mammalian
systems (Koblan et al., 2018). C•G>T•A and A•T>G•C changes
can now be efficiently engineered into cells and animals to model
dominant disease. However, there is a restricted window of
activity 4–8 nucleotides from the first nucleotide of the guide
RNA, and guides can only be designed immediately upstream
of a relevant protospacer adjacent motif (PAM). Engineering
of Cas9 is enabling wider application of this base editing
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technology by adjusting the PAM sequence recognized by Cas9,
so that with the newly engineered Cas9-cytidine deaminase
fusions, approximately 2.5x more variants in ClinVar can be
targeted using the technology (Kim et al., 2017) (Figure 3).
Despite these current limitations, the technology is rapidly
advancing and a “double hit” approach provides an efficient
new method for modeling compound heterozygous mutations
in cell systems. As most ciliopathies are recessive disorders,
and compound heterozygosity is common in individuals from
non-consanguineous unions, this provides a valuable tool for
characterizing variants of unknown significance from the 100,000
Genomes Project.
Characterizing the genetics of ciliopathies may be a larger
challenge than in other rare diseases, due to more complex
genetics, for example the putative oligogenic inheritance in
BBS (Katsanis et al., 2001) and modifier allele effects in multiple
ciliopathies (Khanna et al., 2009; Davis et al., 2011; Cardenas-
Rodriguez et al., 2013), but novel genome editing technologies
provide solutions to these challenges. In order to process the
large volume of variants, high-throughput approaches will need
to be employed, for example high-content imaging screens
such as previously published screens including a whole genome
siRNA knockdown screen in ciliated mouse kidney cell line
IMCD3 (Wheway et al., 2015) and a druggable genome siRNA
knockdown screen in ciliated human retinal cell line hTERT-
RPE1 (Kim et al., 2010).
HEALTH POTENTIAL AND FUTURE
OPPORTUNITIES OF THE 100,000
GENOMES PROJECT
Despite the challenges, there are undoubtedly enormous
opportunities provided by this rich, varied and comprehensively
phenotyped dataset. The project represents one of the greatest
opportunities for novel disease gene discovery, especially in
the case of very rare genes/genetic mutations. The aggregation
of many families into the dataset allows multiple families
with mutations in the same gene to be identified, leading to
disease gene identification. One recent example is PRPS1, a
gene in which heterozygous missense mutations were found
to be carried by retinal dystrophy patients from 5 families
TABLE 2 | Immortalized cell lines used for modeling ciliopathy mutations.
Cell line
name
Species origin Tissue origin Ciliation
in vitro
Transfection ATCC ref References Notes
A6 Xenopus laevis,
frog, South African
clawed
Kidney ** ? CCL-102 Rafferty and
Sherwin,
1969
Requires growth on porous
collagen-coated filters to allow
underside of cells to contact growth
media. Grow very long cilia (up to 50
microns long). Can grow motile cilia.
ARPE-19 Homo sapiens Retina—
pigmented
epithelium
** * CRL-2302 Dunn et al.,
1998
HEK293(T) Homo sapiens Embryonic kidney *? **** CRL-1573;
CRL-6216
Graham et al.,
1977
Often used as an exemplary
transfection host cell line. Not
well-characterized as being ciliated in
culture, but cilia have been described
on these cells. Requires growth on
porous filters to allow underside of
cells to contact growth media
HeLa Homo sapiens Cervix -
adenocarcinoma
* *** CCL-2 Jones et al.,
1971
These are not well-characterized as
being ciliated in culture, but cilia have
been described on these cells.
hTERT-RPE1 Homo sapiens Retina—
pigmented
epithelium
** ** CRL-4000 Rambhatla
et al., 2002
LLC-PK1 Sus scrofa (pig) Kidney—proximal
tubule
** ? CL-101 Perantoni and
Berman,
1979
mIMCD-3 Mus musculus Kidney—inner
medullary
collecting duct
*** *** CRL-2123 Rauchman
et al., 1993
MDCK Canis familiaris Kidney—distal
tubule/collecting
duct
** ** CCL-34 Gaush et al.,
1966
Requires growth on porous filters to
allow underside of cells to contact
growth media.
NIH/3T3 Mus musculus Fibroblast *** *** CRL-1658 Jainchill et al.,
1969
ATCC, American Type Culture Collection; ?, no information available. Asterisks indicate degree of ciliation achieved and ease of transfection in different cell lines.
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FIGURE 3 | Schematic illustration of cytidine deaminase and adenine base editing of the genome. Abbreviations: sgRNA, single guide RNA; BE3, third generation
base editor; ABE, adenine base editor.
in the 100,000 Genomes Project, providing robust genetic
evidence for the cause of this condition. Mutations in PRPS1
are normally found in the more severe Arts syndrome, Charcot-
Marie Tooth, and nonsyndromic sensorineural deafness, so if
mutations in this gene had only been identified in one family,
this may have been disregarded as the pathogenic cause of
disease (Fiorentino et al., 2018).
Furthermore, the aggregation of all rare disease patient
data into one database may enable diagnosis of novel orphan
ciliopathies in a way that was not previously possible. The
extensive phenotypic and genotypic heterogeneity of ciliopathies
raises the likelihood that there exist individuals or groups of
individuals who have a disorder arising from a defect in cilia,
but have not had their condition defined as a ciliopathy. The
collection of all 60,000 rare disease individuals in the 100,000
Genomes Project may enable identification of novel, previously
unrecognized ciliopathies.
In addition to novel disease gene discovery, the project
offers many opportunities to gain novel insights into even the
most basic gene functions. Around 35% of human genes still
have no known function (pantherdb.org) (Figure 4). Functional
genetics studies investigating genes and variants of interest
from the 100,000 Genomes Project may uncover many novel
developmental pathways and gene functionalities.
Such disease gene discoveries and new biological insights
may provide opportunities for developing targeted therapies for
ciliopathies, which currently have very few, if any, treatment
options. A number of studies have investigated the efficacy and
safety of gene therapy for treatment of ciliopathies, particularly
in retinal ciliopathies. RPGR, mutations in which cause up
to 60% of cases of X-linked RP (Vervoort et al., 2000) has
been a particular focus for gene therapy development, including
tested in large mammalian models, which have shown to be
effective in preventing onset of degeneration (Beltran et al.,
2012; Deng et al., 2015; Wu et al., 2015) and also successful
in preventing progression of established disease (Beltran et al.,
2015). More recently, RPGR gene editing approaches have been
developed in addition to existing gene augmentation approaches
(Deng et al., 2018). However, more than 20 years after the
discovery of RPGR, there is still no gene therapy in clinic,
although there are three clinical trials currently recruiting, at
the time of writing (https://clinicaltrials.gov/ct2/results?cond=&
term=rpgr&cntry=&state=&city=&dist=). There are now several
more genes being targeted for gene therapy in retinal ciliopathies
including CEP290 (mutations in which cause LCA10) (Estrada-
Cuzcano et al., 2012; Burnight et al., 2014; Zhang et al., 2018); and
LCA5 (Song et al., 2018). Gene therapy is also being investigated
as a possible treatment for syndromic ciliopathies. Gene
augmentation has been demonstrated to be effective and safe in
Bbs4 genetic mouse models of BBS; (McIntyre et al., 2012, 2013;
Chamling et al., 2013), but the only clinical phenotype which was
rescued was the olfactory sensory defect. It is clear that we need to
look beyond gene therapy for treatment options for ciliopathies.
The extensive genetic heterogeneity underlying these conditions
is a hinderance to development of personalized medicines,
but many recurrent and founder effect mutations are also
found to underlie the ciliopathies. The future of effective drug
development for ciliopathies requires an understanding of the
molecular mechanism of disease, which requires genetic and cell
biology studies that the 100,000 Genomes Project can accelerate.
Much added value will arise from integration of genomics with
multi-omics data (proteomics, transcriptomics, metabolomics,
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FIGURE 4 | Proportion of annotated human protein coding genes with specific functions. Data from pantherdb.org. Thirty-five percentage of human genes have an
unknown function.
epigenomics) and deep phenotyping of ciliopathies, as recently
discussed (Kenny et al., 2017).
Re-purposing and re-licensing of FDA-approved drugs could
be the most rapid way to bring clinical therapeutics to patients.
For example, it has been suggested that re-purposing of cyclin
dependent kinase inhibitors could be an appropriate treatment
option for a broad range of ciliopathies which have a common
basis in replication stress (Slaats et al., 2015). Treatment with
CDK inhibitors such as roscovitine has been shown to be
effective in rescuing cilia defects in cells derived from patients
with Joubert syndrome (Srivastava et al., 2017). Patients with
mutations in NEK1, a DNA damage response gene mutated
in patients with the ciliopathy short rib polydactyly syndrome
(Thiel et al., 2011), could potentially be treated in this manner.
NEK1 interacts with other ciliopathy proteins C21orf2 and
SPATA7 (Wheway et al., 2015), suggesting that other ciliopathies
could likewise be treated with CDK inhibitors. As a center for
Hh signaling, cilia defects can also be potentially treated with
Hh agonists (Hynes et al., 2014), for example purmorphamine,
which has been shown to be effective in rescuing cilia
defects in cells derived from patients with Joubert syndrome
(Srivastava et al., 2017). Uncovering novel mechanisms of
disease through functional characterization of variants in the
100,000 Genomes project ciliopathy patient dataset may well
identify common pathways of disease which can be targeted
to provide therapies for many individuals. Furthermore, if and
when any potential therapies reach clinical trials, the national
genomic registry provided by the 100,000 Genomes Project will
allow rapid identification of individuals suitable for entering
the trial.
Until treatments are developed, perhaps the main advantage
of insights provided by the 100,000 Genomes Project is the
ability to provide genetic diagnosis, for the purposes of better
disease monitoring and management, carrier testing, and family
planning. This is a particularly pressing need for rare, poorly
recognized and difficult to diagnose conditions such as the
ciliopathies. If a genetic diagnosis is made, family members
can undergo carrier testing which can also inform marriage
planning (Nouri et al., 2017; Komlosi et al., 2018). This
is especially useful in communities practicing first cousin
marriage (consanguinity) in which ciliopathies are at higher
risk. One of the aims of the Human Genome Project in
Saudi Arabia, where rates of first cousin marriage are around
40%, is to establish a service whereby every engaged couple
can undergo whole genome sequencing to test for pathogenic
alleles. Worldwide, couples carrying pathogenic variants can
make informed decisions about planning pregnancies, including
options for pre-implantation diagnosis (PGD). Genetic diseases
require robust genetic information before they will be approved
by the Human Fertilization and Embryology Authority (HFEA)
for PGD.Many genetic subtypes of ciliopathies are now approved
for PGD by HFEA, including BBS1, BBS10 and most genetic
subtypes of Joubert syndrome (https://www.hfea.gov.uk/pgd-
conditions/).
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FUTURE PERSPECTIVES FOR UK
MEDICAL GENOMICS
On 31st September 2018, recruitment to the rare disease
pathway of the 100,000 Genomes Project closed. DNA
samples from 61,282 rare disease patients and family members
have been deposited in the UK Biobank and 87,231 whole
genome sequences have been produced, from rare disease
and cancer patients.
Data from the project will continue to provide diagnoses
and uncover novel biological insights for years to come. But
what of the future of genomic testing in the NHS? In place of
the project, from 1st October 2018 the new National Genomic
Medicine Service was established, with an aim to provide
consistent and equitable access to genomic testing services
across the NHS. Genetic testing will now be conducted across
a Genomic Laboratory Network of seven hubs, with choice of
tests available dictated by the National Genomic Test Directory
(https://www.england.nhs.uk/publication/national-genomic-
test-directories/). Of the 190 rare diseases recruited into the
project, neurological, neurodevelopmental conditions and
complex congenital malformations, such as ciliopathies, are
those most likely to continue to benefit from genome testing.
There are now 22 indications for frontline WGS, 12 of which
include ciliopathy phenotypes (Table 3). Bardet-Biedl syndrome
and respiratory ciliopathies will be initially tested using WES or
a large panel test, followed by WGS in year 3 if no results are
found (Table 3).
This represents the largest restructuring of genetic testing in
the history of the NHS and serves as a model for other countries
embarking on similar initiatives. These clinical advances will
be of enormous benefit to patients with complex syndromic
conditions such as ciliopathies. The aim is that WGS will now
be the standard, frontline diagnostic test for many of these
families, and hopefully increases in diagnostic rates beyond 60%
will be start to be achieved. The medical benefits to families of
achieving a rapid diagnosis through WGS for rare diseases like
ciliopathies and the costs saved to the NHS can be calculated
(Mestek-Boukhibar et al., 2018). Studies in the USA have shown
that WGS is by far the most time- and cost-effective way
to achieve a diagnosis for complex, heterogeneous disorders
such as ciliopathies. In the case of general neurodevelopmental
disorders, which are also extensively heterogeneous, WGS can
reduce time to diagnosis by 77 months, reduce cost of diagnosis
by $11,460, and improve clinical care (Soden et al., 2014).
For extremely genetically heterogeneous conditions such as
neurodevelopmental disorders and ciliopathies, WGS provides
an opportunity to allow families to circumvent the traditional
“diagnostic odyssey” (Sawyer et al., 2016). Genomics England
now plan to sequence 5 million genomes over next 5 years.
GLOBAL PERSPECTIVE AND FUTURE
CHALLENGES
There are many other national genome projects around the
world, including many with a focus on understanding rare
disease, cancer, and genomics for precision medicine. Launched
just after the UK’s 100,000 Genomes Project, in December
2013, the Saudi Human Genome Program aims to sequence
100,000 individuals, with a specific focus on understanding rare
inherited disease, common in Saudi Arabia where first-cousin
marriage is common. Two of the largest national genome projects
at the time of writing are the USA’s $215 million Precision
Medicine Initiative announced in January 2015, which aims
to sequence 1 million genomes (https://www.nature.com/news/
us-precision-medicine-proposal-sparks-questions-1.16774) and
China’s genomic medicine initiative, launched in 2016, which
also aims to sequence 1 million genomes, as part of its
13th five-year plan. Two of the longest running are the
Estonia Genome Project (since 2001) and DeCODE project
in Iceland, which has been running since 1996 and has
sequenced 160,000 individuals, a large proportion of the
entire Icelandic population. Others include Genome Russia
Project, Proyecto Genoma Navarra (NAGEN) (Spain), Qatar
Genome Programme, Belgian Medical Genomics Inititative.
More recently, in 2016, France announced its Genomic
Medicine Plan 2025 “Médecine Génomique 2025’ which involves
cooperation with Genomics England, to co-fund analysis of
genomes. More local efforts which are large-scale in terms of
numbers, but are not nationwide include Geisinger MyCode
(Pennsylvania and New Jersey) which has recruited 190,000
patients, and the Utah Genome Project. Transnational efforts
include GenomeAsia100K and international efforts include
the Personal Genome Project. Transnational and international
collaborative efforts may become more commonplace in the
future, to increase the power of shared resources.
As well as state-funded clinical and research genomics
projects, there also exist privately funded genomics projects,
including Craig Venter’s “Human Longevity,” which aims to
sequence 1 million genomes by 2020. AstraZeneca’s genomics
initiative (in partnership with Human Longevity, Genomics
England, Montreal Heart Institute, Sanger Institute and
University of Helsinki) uses retrospective patient data from
clinical trials over the past 10 years, and will continue to collect
data until 2026. In total, up to 2 million genomes will be
sequenced, including 500,000 from patients who have taken
part in AstraZeneca clinical trials, to significantly enhance drug
development for precision medicine approaches.
Each project has different specific aims but they each share
many similarities. They all use Illumina short-read sequencing
technologies, although it seems likely that in the future at
least some will couple these with longer-read sequencing using
platforms such as Pacific Biosciences (PacBio) and Oxford
Nanopore. Most projects are driven by the same financial
initiatives. Since 2008, there has been a global concerted effort
to reduce national spending on healthcare, which in developed
countries typically accounts for spending equivalent to 10–15%
of national GDP (http://www.abpi.org.uk/facts-and-figures/
global-pharmaceutical-market/global-health-expenditure-as-a-
share-of-gdp/). The Saudi Human Genome Program estimates
the total global annual cost of treating rare inherited disease
at around US$27 billion (Project Team, 2015). A substantial
reduction in children born with genetic disabilities, as a result
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TABLE 3 | Conditions indicated for WGS diagnosis in the UK NHS.
Clinical indication Optimal
family
structure
Test method year 1 Test method year 2 Test method year 3
Acutely unwell infants with a likely monogenic disorder Trio WGS WGS WGS
Ultra-rare and atypical monogenic disorders Trio or
singleton
WGS WGS WGS
Congenital malformation and dysmorphism
syndromes—likely monogenic
Trio WGS WGS WGS
Moderate, severe or profound intellectual disability Trio WGS WGS WGS
Floppy infant with a likely central cause Trio WGS WGS WGS
Skeletal dysplasia Trio WGS WGS WGS
Rare syndromic craniosynostosis or isolated multisuture
synostosis
Trio WGS WGS WGS
Neonatal diabetes Trio WGS WGS WGS
Likely inborn error of metabolism—targeted testing not
possible
Trio WGS WGS WGS
Hereditary ataxia with onset in adulthood Singleton WGS WGS WGS
Hereditary ataxia with onset in childhood Trio or
singleton
WGS WGS WGS
Early onset or syndromic epilepsy Trio WGS WGS WGS
Childhood onset hereditary spastic paraplegia Trio or
singleton
WGS WGS WGS
Arthrogryposis Trio WGS WGS WGS
Other rare neuromuscular disorders Trio or
singleton
WGS WGS WGS
Cerebellar anomalies Trio WGS WGS WGS
Holoprosencephaly—NOT chromosomal Trio WGS WGS WGS
Hydrocephalus Trio WGS WGS WGS
Cerebral malformation Trio WGS WGS WGS
Severe microcephaly Trio WGS WGS WGS
Childhood onset leukodystrophy Trio WGS WGS WGS
Cystic renal disease Singleton WGS WGS WGS
Parental sequencing for lethal autosomal recessive
disorders
Parents only WES WES WGS
Bardet-Biedl syndrome Singleton WES or large panel WES or large panel WGS
Fetal anomalies with a likely genetic cause Singleton WES or large panel WES or large panel WGS
Hypertrophic cardiomyopathy—teen and adult Singleton WES or large panel WES or large panel WES or large panel
Dilated cardiomyopathy—teen and adult Singleton WES or large panel WES or large panel WES or large panel
Molecular autopsy Singleton WES or large panel WES or large panel WES or large panel
Progressive cardiac conduction disease Singleton WES or large panel WES or large panel WES or large panel
Thoracic aortic aneurysm or dissection Singleton WES or large panel WGS WGS
Pediatric or syndromic cardiomyopathy Singleton WES or large panel WES or large panel WGS
Primary lymphoedema Singleton WES or large panel WES or large panel WGS
Non-syndromic hearing loss Singleton WES or large panel WES or large panel WGS
Monogenic diabetes Singleton WES or large panel WES or large panel WES or large panel
Growth failure in early childhood Singleton WES or large panel WGS WGS
Bilateral congenital or childhood onset cataracts Singleton WES or large panel WGS WGS
Retinal disorders Singleton WES or large panel WES or large panel WGS
Structural eye disease Singleton WES or large panel WES or large panel WGS
Cholestasis Singleton WES or large panel WES or large panel WES or large panel
Disorders of sex development Singleton WES or large panel WGS WGS
Possible X-linked retinitis pigmentosa Singleton WES or large panel WES or large panel WGS
Sorsby retinal dystrophy Singleton WES or large panel WES or large panel WGS
(Continued)
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TABLE 3 | Continued
Clinical indication Optimal
family
structure
Test method year 1 Test method year 2 Test method year 3
Doyne retinal dystrophy Singleton WES or large panel WES or large panel WGS
Polycystic liver disease Singleton WES or large panel WES or large panel WES or large panel
Infantile inflammatory bowel disease Singleton WES or large panel WES or large panel WES or large panel
Bleeding and platelet disorders Singleton WES or large panel WES or large panel WGS
Rare anemia Singleton WES or large panel WES or large panel WGS
Cytopenia—NOT Fanconi anemia Singleton WES or large panel WES or large panel WGS
Cytopenia—Fanconi breakage testing indicated Singleton WES or large panel WES or large panel WGS
Thrombophilia with a likely monogenic cause Singleton WES or large panel WES or large panel WES or large panel
Primary immunodeficiency Singleton WES or large panel WGS WGS
Glycogen storage disease Singleton WES or large panel WES or large panel WES or large panel
Lysosomal storage disorder Singleton WES or large panel WES or large panel WES or large panel
Mitochondrial DNA maintenance disorder Singleton WES or large panel WGS WGS
Mitochondrial disorder with complex I deficiency Singleton WES or large panel WGS WGS
Mitochondrial disorder with complex II deficiency Singleton WES or large panel WGS WGS
Mitochondrial disorder with complex III deficiency Singleton WES or large panel WGS WGS
Mitochondrial disorder with complex IV deficiency Singleton WES or large panel WGS WGS
Mitochondrial disorder with complex V deficiency Singleton WES or large panel WGS WGS
Possible mitochondrial disorder—nuclear genes Singleton WES or large panel WGS WGS
Ehlers Danlos syndrome with a likely monogenic cause Singleton WES or large panel WES or large panel WES or large panel
Osteogenesis imperfecta Singleton WES or large panel WES or large panel WES or large panel
Adult onset dystonia, chorea or related movement
disorder
Singleton WES or large panel WES or large panel WGS
Childhood onset dystonia, chorea or related movement
disorder
Singleton WES or large panel WES or large panel WGS
Adult onset neurodegenerative disorder Singleton WES or large panel WGS WGS
Adult onset hereditary spastic paraplegia Singleton WES or large panel WGS WGS
Adult onset leukodystrophy Singleton WES or large panel WGS WGS
Paroxysmal neurological disorders, pain disorders and
sleep disorders
Singleton WES or large panel WES or large panel WGS
Hereditary neuropathy—NOT PMP22 copy number Singleton WES or large panel WGS WGS
Congenital muscular dystrophy Singleton WES or large panel WGS WGS
Congenital myaesthenic syndrome Singleton WES or large panel WGS WGS
Congenital myopathy Singleton WES or large panel WGS WGS
Limb girdle muscular dystrophy Singleton WES or large panel WGS WGS
Neuromuscular arthrogryposis Singleton WES or large panel WGS WGS
Cerebral vascular malformations Singleton WES or large panel WES or large panel WES or large panel
Renal tubulopathies Singleton WES or large panel WES or large panel WES or large panel
Nephrocalcinosis or nephrolithiasis Singleton WES or large panel WES or large panel WES or large panel
Unexplained pediatric onset end-stage renal disease Singleton WES or large panel WES or large panel WES or large panel
Proteinuric renal disease Singleton WES or large panel WGS WGS
Laterality disorders and isomerism Singleton WES or large panel WES or large panel WES or large panel
Respiratory ciliopathies including non-CF bronchiectasis Singleton WES or large panel WES or large panel WES or large panel
Epidermolysis bullosa and congenital skin fragility Singleton WES or large panel WES or large panel WES or large panel
Neonatal erythroderma Singleton WES or large panel WES or large panel WES or large panel
of improved genetic diagnostics through understanding gained
from genome projects, could immediately save over US$270
million. Furthermore, most governments cite the importance
of remaining, or becoming, internationally competitive in the
nascent field of genome-guided drug development as reasons
behind their investment in large-scale genomics projects. The
pharmaceutical industry is one of the world’s largest industries,
worth in excess of $800,000 million annually (http://www.abpi.
org.uk/facts-and-figures/global-pharmaceutical-market/top-10-
pharmaceutical-markets-by-value-usd/).
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In order to achieve the greatest global health benefits from the
information in these multiple genomics projects, responsible and
secure data sharing is essential. Achieving this whilst maintaining
patient confidentiality and data security is a global challenge.
The Global Alliance for Genomics and Health (GA4GH) was
established in 2013 to develop best-practice guidelines, and
develop tools for genome data sharing. Most recently, GA4GH
have developed the application programming interface (API)
Beacon, which allows organizations to share genomic and
health data in a way which preserves patient confidentiality
and data anonymity. Through Beacon, individuals who are
not registered and approved users of individual genomics
datasets, such as a GeCIP member, can still query these datasets
to retrieve information about specific alleles. This saves time;
there is no need to go through an often lengthy database access
protocol and it actually preserves patient confidentiality since
no raw genome data is accessed. Beacon is part of the new
interoperability standards, contributing to the Framework for
Responsible Sharing of Genomic and Health-Related Data
developed by GA4GH (https://www.ga4gh.org/genomic-data-
toolkit/regulatory-ethics-toolkit/framework-for-responsible-
sharing-of-genomic-and-health-related-data/). Congenica and
Genomics England are members of the GA4GH and contribute
to the Steering Committee of GA4GH, so it seems likely that at
some point in the future data will become more widely available
for exploitation for the benefit of human health.
Meaningful and effective sharing of data from many
genome projects also poses a practical challenge in terms
of interoperability of analytical platforms. Whilst all large
scale genome projects predominantly use Illumina sequence
technologies, each program has bespoke data standards,
analytical pipelines, storage and access protocols which are
potentially incompatible with each other. There may also be
variations in the standards applied to use of phenotypic terms,
variant calling and descriptions of pathogenicity of alleles.
GA4GH develops tools and defines standards to harmonize
data generation, analysis, storage and access. Recently, GA4GH
developed a set of standards for variant calling, which allows
stratification of performance by variant type and genome
context (Krusche et al., 2018). Furthermore, GA4GH develops
standards for workflow development, and APIs for packaging of
workflows to support their application within multiple different
environments. This will allow researchers to run the same
analysis workflow on data in multiple clouds and environments
in order to standardize data analysis across projects.
Ensuring interoperability of platforms will becoming
increasingly important as more genome projects incorporate
long-read sequence technologies to complement short-read
sequence technologies. This approach allows resolution and
alignment of repetitive regions, including regions with many
short tandem repeats, or genes with many pseudogenes, phasing
of compound heterozygous mutations and provides information
about epigenetic marks (Simpson et al., 2017; Pollard et al., 2018).
This has clinical relevance in ciliopathies; ADPKD associated
with PKD1 mutations is difficult to diagnose genetically due to 6
pseudogenes of PKD1 on chromosome 16 with 97.7% sequence
identity (Eisenberger et al., 2015). Similarly, in the X-linked
retinal ciliopathy retinitis pigmentosa, diagnostic yields are
low due to the fact that most patients have a mutation in the
highly repetitive region of RPGR ORF15, which is difficult to
amplify by PCR and Sanger sequencing, and difficult to align
with Illumina short read sequencing (Vervoort et al., 2000;
Branham et al., 2012).
As well as ensuring integration of different sequencing
analysis platforms, it is essential to ensure that platforms for
sequence storage and analysis integrate properly with electronic
clinical data management systems. This is particularly important
for reporting and genetic counseling, and clinical management
of patients in receipt of a genetic diagnosis (Welch et al., 2018).
It is also crucial to the meaningful analysis of genome data, in
the context of detailed medical records including family history,
phenotype (using standard HPO terms) and treatment history.
GA4GH have developed best practice guidelines for using Family
Health History patient record systems with genomics data.
Complex challenges remain, including standardizing a
definition of what constitutes a pathogenic allele across all
genomics projects. The Association for Clinical Genetic Science’s
Best Practice Guidelines for Variant Classification 2017 (Ellard
et al., 2017) forms the basis of the standard for the 100,000
Genomes Project, based upon Standards and Guidelines for
the Interpretation and Reporting of Sequence Variants in
Cancer published by the Association for Molecular Pathology
(Li et al., 2017). However, it must be acknowledged that we
remain relatively naïve in our understanding of pathogenicity,
particularly with regard to variants affecting splicing. It has
been calculated that 35-40% of pathogenic variants in non-
canonical splice site positions are missing from public databases,
suggesting that we currently under-diagnose pathogenic causes
of disease associated with splicing (Lord et al., 2018). We
do not yet know enough about the functional effect of non-
coding variants, subtle missense variants and variants in exonic
splice enhancers to be able to report these back to patients
without functional validation. This is likely to be the significant
bottleneck in exploitation of the expanding wealth of genome
and population-genetics data. Most in silico predictors of
pathogenicity are notoriously unreliable, and will only improve
with machine learning aided by robust in vitro data from
functional experiments. This is time-consuming and expensive
work. Beyond simple monogenic disorders, we also need
frameworks for consistently assigning pathogenicity based on
polygenic risk scores, and combined total gene variation scores
(Khera et al., 2018; Mossotto et al., 2018). For these reasons,
it seems appropriate that this remains an ongoing area of
development by GA4GH’s Variation Annotation Task Team.
GLOBAL SOCIAL CHALLENGES
The UK, USA and China all strive to be global leaders in this area,
and as a result, have each launched ambitious genome sequencing
projects such as the 100,000 Genomes Project, arguably before
the necessary skills, understanding or, importantly, public
appetite, to manage these projects effectively is in place. Public
understanding and trust of genomics remains a global challenge
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to the success of all genomics projects. Lack of understanding
or confidence in genomics in the workforce and the patient
population poses a barrier to effective implementation and
recruitment to genomics projects. This requires an entire
“Workforce transformation” (https://www.genomicseducation.
hee.nhs.uk/news/item/357-transforming-healthcare-the-
impact-of-genomics-on-the-nhs/). Health Education England,
(HEE) is a key delivery partner in the 100,000 Genomes Project
and has developed a Genomics Education Programme delivered
by higher education providers around the UK as a postgraduate
masters (MSc) in Genomic Medicine. Parts of this programme
are also possible to study, with a shorter training period, awarded
as a PGCert and PGDip, or as standalone modules available as
part of continuing professional development (CPD). Courses are
designed to fit around work, or to be attended part-time, by staff
within the NHS and a One-day Primer In Genomic Medicine is
currently offered by University of Southampton (https://www.
southampton.ac.uk/medicine/primer-in-genomic-medicine-
web-form.page; https://www.genomicseducation.hee.nhs.uk/
taught-courses/courses/primer-genomic-medicine/.
Patient education and education of the general public in
genomics remains a barrier to greater success and higher
recruitment, and impacts on truly “informed consent.”
Furthermore, the nature of a consent process in which
all individuals must consent to the research element of
the project, which includes sharing of information with
commercial companies, raises issues around autonomy and
consent (Dheensa et al., 2018). The public outreach initiative
“Socializing the Genome,” developed by West of England
Genomic Medicine Center, reached 19,000 people across the
south-west, now launched across Manchester region (https://
www.genomicseducation.hee.nhs.uk/news/item/347-how-lego-
pro-bots-are-bringing-genomics-to-life-in-the-classroom/). At
a time when public understanding, including in the workforce,
remains low, there is concern that mainstreaming of genomics
services at this point in time may be premature (Ormondroyd
et al., 2018). Ethical implications of incidental findings, data
security and anonymity, and intellectual property of findings
resulting from genome studies also remain unresolved issues
across all projects. Many professionals currently believe
incidental findings should be reported with caution, with an
“approach that is responsive to accumulating evidence.” These
issues present a significant challenge (Ormondroyd et al., 2018).
The general consensus is that there is not enough evidence
to form a robust policy regarding secondary findings yet, so
data should be interpreted with caution (Ormondroyd et al.,
2018). Similarly, decisions about how often to reanalyze data
and the mechanism for reporting data back to patients still
requires resolution.
It is of utmost importance for healthcare professionals,
researchers, and policymakers to be open and honest about the
challenges, in order to avoid “genohype” and setting unrealistic
expectations. In the past there has been a tendency to overstate
the opportunities and understate the risks associated with
genetic testing (Samuel and Farsides, 2017) and this has led
to some loss of public confidence in genetics. Time taken to
return findings remains a significant issue in genomic testing
(Moss and Wernham, 2018). Transparency, clear and ongoing
communication between healthcare professionals and patients is
essential (Dheensa et al., 2018), communicating the possibility of
no certain findings either now, or in the near future. We also
need to reconsider our concept of the need for fully informed
consent, which may not be possible in genomics. Rather, we must
consider the general social contract around healthcare provision
in the UK, and commitments to public education in the area
of genomics.
CONCLUDING REMARKS
The 100,000 Genomes Project provides many opportunities and
challenges to improve our understanding of ciliopathies. Perhaps
the real power in this dataset will be realized through aggregation
of this information with other genome projects worldwide. For
this to be a success, data security, regulation and ethics must
be at the center of such efforts, to establish and maintain
public trust in genome testing. There must be a truly global
effort to standardize phenotypic descriptions, data standards,
analysis pipelines and mechanisms for data sharing and
discovery. Perhaps then, with global cooperation, we can finally
increase diagnostic yields, inform better clinical management
and translate new understanding into targeted therapies for
ciliopathy patients.
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